GlassScriptPhysician profile
John M Tolbert
NPI 1811961345
$14,565.82
in general payments reported to CMS, 2019-2025
27 companies · $2,711 in 2025
The $2,711 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,097 · 2022: $3,109 · 2023: $2,669 · 2024: $3,979 · 2025: $2,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,159 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,158.98 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,328.93 | 2021-2025 | |
| Abbvie INC. | $1,943.24 | 2021-2025 | |
| Janssen Biotech, INC. | $1,189.83 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Ucb, INC. | $1,088.08 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $1,039.63 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $919.27 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $844.41 | 2021-2025 | |
| Lilly USA, LLC | $774.82 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Dermavant Sciences, INC. | $740.20 | 2022-2024 | Vtama |
| Incyte Corporation | $693.22 | 2021-2024 | Opzelura |
| Amgen INC. | $658.48 | 2021-2025 | Otezla, Otezla |
| Pfizer INC. | $564.64 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $384.90 | 2021-2025 | Ilumya, Winlevi |
| Leo Pharma INC. | $366.66 | 2021-2025 | Adbry |
| Mayne Pharma Commercial LLC | $214.79 | 2022-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $195.75 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $119.26 | 2021-2025 | Nemluvio |
| Almirall LLC | $105.00 | 2021-2025 | Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $94.38 | 2021-2025 | Siliq, Cabtreo, Jublia |
| Sanofi-Aventis U.S. LLC | $72.00 | 2021 | |
| Botanix Sb INC | $71.55 | 2025 | Sofdra |
| Organogenesis INC. | $51.25 | 2023-2024 | Puraply |
| Genentech USA, INC. | $30.07 | 2021-2024 | Erivedge |
| Surgenex LLC | $24.01 | 2025 | Surmatrix, Pellograft, Surgraft |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.44 | 2023 | Spevigo |
| Medtronic, INC. | $16.22 | 2022 | |
| Kerecis Limited | $13.79 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tolbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.